Bionor Holding AS is a privately held Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccines Vacc-4x and Vacc-C5 towards a functional HIV cure. To date, Bionor has invested more than USD 100 million in technology, preclinical and clinical development research.
Bionor Immuno AS was a spin-off from Bionor AS, founded in 1985 in Skien, Norway with a focus on developing diagnostic tests for viral diseases. Bionor Immuno AS decided to leverage its immunology expertise by exploring the use of its proprietary compounds for viral diseases in the development of peptide vaccines.
Bionor Immuno AS is 100% owned by Bionor Holding AS. The acquisition of Bionor Immuno was completed late autumn 2017.
Bionor’s product pipeline consists of three products which are the backbone of the Functional HIV Cure strategy.
The 3 product candidates Vacc-4x, Vacc-C5 and CRX serves different functions in this strategy.